Mo Khan CEO of hVIVO, 2022 in Review

Mo Khan CEO of hVIVO #HVO discusses some of their highlights in 2022, which includes contracted orders of £80m+, having a client base which includes four of the top 10 largest global biopharma companies and their name change. Mo also outlines his expectations for 2023

00:00 Introduction
00:38 Year in Review 2022
08:10 2023 for hVIVO

You might like

© 2022 The Latest StockMarket News and Interviews